SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Jade Biosciences doses first patient

Jade Biosciences starts JADE201 trial, a significant step for the company's development pipeline. This trial may impact the biotech sector.

JADE
SquawkNews Desk

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories

Georgia Banking Co. Shares Trade at $40.15 After Opening at $60 Shares traded at $40.15 after opening at $60 in the company's Nasdaq debut via direct listing. Its prospectus said stockholders would sell up to 7.07 million shares. M impact | EQUITY | Oct 29, 2026, 07:24 PM UTC Medical Properties Trust Reports Quarterly Results Medical Properties Trust reported results for the quarter ended September 30. M impact | EQUITY | Oct 29, 2026, 07:24 PM UTC Volkswagen Avoids Puebla Plant Strike With 8.24% Employee Raise Volkswagen will give employees at its Puebla plant an 8.24% raise this year, averting a strike. M impact | EQUITY | Oct 29, 2026, 07:23 PM UTC Federal Signal Reports Q3 2026 Revenue of $655.5M, EPS of $1.29 Third-quarter net income was $79.6 million. Revenue rose 18.1%, net income 16.9% and diluted EPS 16.2% from the prior-year quarter. M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC Peoples Bancorp Reports Third-Quarter 2026 Revenue of $119.5 Million Revenue rose 3.8% year over year to $119.5 million. Net income increased 10.6% to $32.6 million, while diluted EPS rose to $0.91 from $0.83. M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC Axalta Reports Third-Quarter 2026 Revenue of $1.31 Billion Revenue rose 1.8% year over year to $1.31 billion, while net income declined 13.6% to $95 million and diluted EPS fell 13.7% to $0.44. M impact | EQUITY | Oct 29, 2026, 07:21 PM UTC